Nisa Investment Advisors’s Zevra Therapeutics ZVRA Stock Holding History

Nisa Investment Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1K	Sell	118 -734	-86%	-$6.62K	﹤0.01%	2731
2025 Q4	$7.63K	Hold	852	–	–	﹤0.01%	2335
2025 Q3	$8.1K	Hold	852	–	–	﹤0.01%	2339
2025 Q2	$7.51K	Buy	852 +641	+304%	+$5.2K	﹤0.01%	2367
2025 Q1	$1.58K	Buy	211 +93	+79%	+$739	﹤0.01%	2529
2024 Q4	$984	Hold	118	–	–	﹤0.01%	2690
2024 Q3	$819	Hold	118	–	–	﹤0.01%	2621
2024 Q2	$578	Buy	+118	New	+$559	﹤0.01%	2654
2023 Q4	–	Sell	-2,500	Closed	-$12.1K	–	2766
2023 Q3	$12.1K	Buy	+2,500	New	+$12.5K	﹤0.01%	2139
2022 Q1	–	Sell	-3,650	Closed	-$26K	–	2412
2021 Q4	$26K	Buy	+3,650	New	+$32.6K	﹤0.01%	1881

Other funds holding ZVRA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Nisa Investment Advisors's ZVRA Position: Q1 2026 in Review

Nisa Investment Advisors reduced its Zevra Therapeutics (ZVRA) stake by 86% in Q1 2026, selling an estimated $6.62K and leaving 118 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2731.

Nisa Investment Advisors first reported a position in ZVRA in Q4 2021 and has held it in 10 quarters since. The position peaked at $26K in Q4 2021. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

Nisa Investment Advisors held 118 shares of Zevra Therapeutics worth $1.1K as of Q1 2026.
Nisa Investment Advisors sold 734 Zevra Therapeutics shares in Q1 2026, an estimated $6.62K.
Zevra Therapeutics made up ﹤0.01% of Nisa Investment Advisors's portfolio in Q1 2026, its #2731 holding.
Nisa Investment Advisors first reported a position in Zevra Therapeutics in Q4 2021 and has held it in 10 quarters since.
Nisa Investment Advisors's Zevra Therapeutics position peaked at $26K in Q4 2021.
148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Nisa Investment Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.